Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Over the past six months, Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, ...

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In ...

Bristol Myers Squibb’s Fundamentals Over Recent Years. Bristol Myers Squibb’s revenue increased from $26 billion in 2019 to $46 billion in 2022, partly aided by its Celgene CELG acquisition in ...

Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb and Bain Capital are forming a new biopharmaceutical company focused on therapies for autoimmune diseases. The new company will be created with $300 million in financing led by ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...